Picture loading failed.

Anti-IL23A therapeutic antibody (Pre-made Guselkumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Guselkumab, sold under the brand name Tremfya, is a monoclonal antibody against interleukin-23 used for the treatment of plaque psoriasis.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-255-1mg 1mg 3090
GMP-Bios-ab-255-10mg 10mg 21890
GMP-Bios-ab-255-100mg 100mg 148000
GMP-Bios-ab-255-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-IL23A therapeutic antibody (Pre-made Guselkumab biosimilar,Whole mAb)
INN Name Guselkumab
TargetIL23A
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCLambda
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI Structure4m6m:HL/4m6n:HL
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2013
Year Recommended2014
CompaniesJanssen Biotech;MorphoSys;Taiho Pharmaceutical
Conditions ApprovedErythrodermic psoriasis;Palmoplantar pustulosis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis
Conditions ActiveCrohn's disease;Hidradenitis suppurativa;Ulcerative colitis;Familial adenomatous polyposis;Psoriasis;Giant cell arteritis;Lupus nephritis;Systemic scleroderma
Conditions DiscontinuedRheumatoid arthritis
Development TechMorphoSys HuCAL Phage Display